The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of dovitinib in combination with capecitabine and oxaliplatin in upfront treatment of advanced colorectal and gastric cancer with a dose expansion cohort in advanced gastric cancer.
W. M. D. Tai
No relevant relationships to disclose
W. S. Ooi
No relevant relationships to disclose
J. Y. Ngeow
No relevant relationships to disclose
N. Deng
No relevant relationships to disclose
H. Wang
No relevant relationships to disclose
C. K. Tham
No relevant relationships to disclose
H. Y. Lim
No relevant relationships to disclose
S. P. Choo
No relevant relationships to disclose
P. Tan
Research Funding - Novartis
H. C. Toh
Research Funding - Novartis
I. B. Tan
Research Funding - Novartis